Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc. (TPTX) priced its initial public offering on Apr 18, 2019 at $18.00 per share, within its $16.00–$18.00 range, raising $166.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $533.8M. Goldman Sachs was lead-left underwriter, joined by Leerink Partners, Wells Fargo and Canaccord Genuity. Cooley advised the company and Davis Polk advised the underwriters.

Turning Point Therapeutics, Inc. is a pharmaceutical company working on kinase inhibitor cancer therapies. It sees an opportunity for a new generation of tyrosine kinase inhibitors that address the treatment resistance and toxicity limits of current drugs in this class.

Status

IPO

Ticker

TPTX

Exchange

Nasdaq Global Select

Priced

Apr 18, 2019

IPO price

$18.00

Price range

$16.00–$18.00

Raised

$166.5M

Market cap at IPO price

$533.8M

First filed

Mar 21, 2019

Underwriters

Goldman Sachs, Leerink Partners, Wells Fargo and Canaccord Genuity

Company counsel

Cooley

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.